The binding of MET with its ligand (hepatocyte growth factor) activates downstream signaling pathways, including phosphoinositide 3-kinase (PI3K)/Akt, Ras-Rac/Rho, MAPK, and phospholipase C-γ [64], frequently activated in human cancers [68]. This evidence concerns the gene MET and cancer.